Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. Research and Clinical Diagnostic Tests and Controls
  4. Allergy, Arthritis and Immunology Testing
  5. Immunoassay and Immunology Controls
  6. OCD6905560

QuidelOrtho VITROS™ Immunodiagnostic Products B·R·A·H·M·S PCT Controls

Catalog No. OCD6905560
Change view
Click to view available options
Quantity:
3 Levels, 1 mL Vials
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
OCD6905560 3 Levels, 1 mL Vials
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. OCD6905560 Supplier QuidelOrtho Supplier No. 6905560
Only null left
Add to Cart
Add to Cart

Description

QuidelOrtho B·R·A·H·M·S PCT is a biomarker for early bacterial infection diagnosis and antibiotic stewardship

Test delivers:

  • High sensitivity and specificity for bacterial infection enables therapeutic decision making
  • Results that are ready to be delivered to a clinicians with 96.5% First Pass Yield (without user intervention)
  • Analytical performance: LOD at 0.007 ng/mL, LOQ (20% CV, observed) at 0.013 ng/mL
  • Fast turnaround time: 24 minutes to first result
  • Reliable solution: Not impacted by biotin interference

Indicated as an aid to be used in conjunction with clinical evaluation for:

  • Risk assessment of critically ill patients on their first day of ICU admission for progression to severe sepsis and septic shock
  • Assessing the cumulative 28-day risk of all-cause mortality for patients diagnosed with severe sepsis or septic shock in the ICU or when obtained in the emergency department or other medical wards prior to ICU admission, using a change in PCT level over time
  • Decision making on antibiotic therapy for patients with suspected or confirmed lower respiratory tract infections (LRTI) defined as community-acquired pneumonia (CAP), acute bronchitis, and acute exacerbation of chronic obstructive pulmonary disease (AECOPD) – in an inpatient setting or an emergency department
  • Decision making on antibiotic discontinuation for patients with suspected or confirmed sepsis

Indicated for use with the VITROS™ ECi/ECiQ/3600 Immunodiagnostic Systems and the VITROS™ 5600/XT 7600 Integrated Systems.

Specifications

Assay Target Procalcitonin
For Use With (Equipment) VITROS™ ECi/ECiQ/3600 Immunodiagnostic Systems and VITROS™ 5600/XT 7600 Integrated Systems
Type Controls
Quantity 3 Levels, 1 mL Vials
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.